Washington University School of Medicine announces a new clinical trial for COVID-19 positive patients, STOP COVID Trial. Many patients testing positive for COVID-19 initially experience mild symptoms, but then clinically deteriorate in the second week of illness.
The STOP COVID Trial tests a medication (fluvoxamine) for its anti-COVID properties for individuals ages 30 and up who have recently tested positive for COVID-19 (within 6 days), and are symptomatic. The goal of this study is to determine if a brief course of fluvoxamine can prevent the deterioration that occurs in 10-20% of patients.
In a preliminary study published in JAMA, the investigators showed fluvoxamine prevented clinical deterioration (dyspnea and hypoxia).
This is an “at-home” clinical trial – patients participate from the safety of their own home with remote monitoring.
Adults who recently tested positive should:
- Visit us online at http://stopcovidtrial.wustl.edu
- Email us at email@example.com; or
- Call us at (314)747-1134
Lead investigators of the study include:
Eric Lenze, MD
Professor of Psychiatry
Caline Mattar, MD
Assistant Professor of Medicine, Infectious Disease
Angela Reiersen, MD
Associate Professor of Psychiatry